NCT05366036View on ClinicalTrials.gov

A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

172

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions
Multiple Sclerosis, Relapsing-remitting
Interventions
OTHER

No Intervention

This is a non-interventional study.

Trial Locations (20)

Unknown

Site #20, Cheonan

Site #15, Ansan

Site #08, Bucheon-si

Site #09, Goyang-si

Site #14, Goyang-si

Site #23, Changwon

Site #13, Jinju

Site #02, Busan

Site #16, Busan

Site #01, Daegu

Site #17, Daegu

Site #07, Daejeon

Site #03, Kwangju

Site #04, Seoul

Site #06, Seoul

Site #11, Seoul

Site #12, Seoul

Site #18, Seoul

Site #19, Seoul

Site #21, Seoul

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY

NCT05366036 - A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter